Related Experiment Video
Updated: May 21, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Janus-like effects of type I interferon in autoimmune diseases
Robert C Axtell1, Chander Raman
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305-5316, USA. axterobe@stanford.edu
Abstract:
In multiple sclerosis, type I interferon (IFN) is considered immune-modulatory, and recombinant forms of IFN-β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing-remitting multiple sclerosis (RRMS) population, 30-50% of MS patients are non-responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro-inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.
More Related Videos
Related Concept Videos
Type I Diabetes II: Pathophysiology
Inhibitors of Viral Protein Synthesis
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Type I Diabetes I: Introduction
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
The JAK-STAT Signaling Pathway

